0
Signin
countryflagUS

18889881171

AAPL 183.36 5.9701% MSFT 406.8 2.2522% GOOG 169.01 0.3265% GOOGL 167.21 0.3541% AMZN 186.235 0.8202% NVDA 887.83 3.4562% META 452.05 2.3479% TSLA 181.14 0.6277% TSM 141.56 3.9125% LLY 734.97 -2.7702% V 268.47 0.3214% AVGO 1278.11 3.1924% JPM 190.51 -0.6% UNH 492.45 -0.1055% NVO 123.05 -0.7821% WMT 59.82 0.1842% LVMUY 168.5 2.1584% XOM 116.02 -0.1893% LVMHF 841.0 1.8789% MA 443.58 0.5622%

Processa Pharmaceuticals Inc

Healthcare US PCSA

2.17USD
-0.09(3.98%)

Last update at 2024-05-03T20:00:00Z

Day Range

2.152.30
LowHigh

52 Week Range

0.181.45
LowHigh

Financials

Income Statement

Balancesheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -27.42423M -11.95815M -15.41481M -3.96059M -4.66785M
Minority interest - - - - 0.00000M
Net income -54.84846M -11.42753M -14.41379M -3.35788M -3.76505M
Selling general administrative 8.76M 4.69M 3.26M 1.61M 1.44M
Selling and marketing expenses - - - - -
Gross profit -27.52543M -12.13354M -15.13686M - 0.00000M
Reconciled depreciation 0.79M 0.79M 0.80M 0.80M 0.63M
Ebit -27.52543M -12.13354M -15.13686M -3.93548M -4.50664M
Ebitda -12.20065M -10.76400M -5.62991M -3.12016M -3.87655M
Depreciation and amortization 15.32M 1.37M 9.51M 0.82M 0.63M
Non operating income net other - - 0.00317M - 0.00000M
Operating income -27.52543M -12.13354M -15.13686M -3.93548M -4.52494M
Other operating expenses 20.26M 11.57M 6.44M 3.94M 4.52M
Interest expense 0.10M 0.00036M 0.28M 0.04M 0.16M
Tax provision 0.00000M -0.53061M -1.00102M -0.60272M -0.90280M
Interest income 0.10M 0.01M 0.00317M 0.01M 0.02M
Net interest income 0.10M 0.01M -0.27795M -0.02511M -0.14291M
Extraordinary items - - - - 0.00000M
Non recurring - - - - 0.00000M
Other items - - - - 0.00000M
Income tax expense 27.42M -0.53061M -1.00102M -0.60272M -0.90280M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 20.26M 11.57M 6.44M 3.94M 4.52M
Cost of revenue 27.53M 12.13M 15.14M - 0.00000M
Total other income expense net 0.10M 0.18M -0.27795M -0.02511M -0.14291M
Discontinued operations - - - - 0.00000M
Net income from continuing ops -27.42423M -11.42753M -14.41379M -3.35788M -3.76505M
Net income applicable to common shares - -11.42753M -19.03974M -3.86487M -3.76505M
Preferred stock and other adjustments - - - - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 8.62M 26.46M 25.21M 10.88M 13.21M
Intangible assets - 8.06M 8.85M 9.64M 10.44M
Earning assets - - - - -
Other current assets 1.88M 1.76M 0.55M 0.32M 0.26M
Total liab 1.15M 0.98M 2.27M 2.87M 3.51M
Total stockholder equity 7.47M 25.49M 22.94M 8.01M 9.70M
Deferred long term liab - - 0.53M - 0.00000M
Other current liab 0.59M 0.68M 0.70M 0.24M 0.12M
Common stock 0.00161M 0.00157M 0.00142M 0.00055M 0.00387M
Capital stock 0.00161M 0.00157M 0.00142M 0.00055M 0.00387M
Retained earnings -64.24756M -36.82333M -25.39580M -10.98201M -7.62413M
Other liab - - 0.93M 1.53M 2.13M
Good will - - - - 0.00000M
Other assets - 0.00553M 0.16M 0.00553M 0.73M
Cash 6.50M 16.50M 15.42M 0.69M 1.74M
Cash and equivalents - - - - -
Total current liabilities 1.00M 0.97M 1.22M 1.19M 0.65M
Current deferred revenue - - - - -
Net debt -6.27414M -16.41912M -15.08810M 0.34M -1.51096M
Short term debt 0.08M 0.07M 0.20M 0.88M 0.23M
Short long term debt - - 0.12M 0.80M 0.23M
Short long term debt total 0.23M 0.08M 0.33M 1.03M 0.23M
Other stockholder equity 71.72M 62.31M 48.33M 18.99M 17.32M
Property plant equipment - 0.07M 0.16M 0.23M 0.02M
Total current assets 8.39M 18.33M 16.20M 1.01M 2.02M
Long term investments - - - - 0.00000M
Net tangible assets - 17.43M 14.09M -1.62990M -0.73676M
Short term investments - - - - 0.00000M
Net receivables - 0.07M 0.23M - 0.02M
Long term debt - - 0.04M - 0.00000M
Inventory - - - - 0.00000M
Accounts payable 0.33M 0.22M 0.32M 0.08M 0.29M
Total permanent equity - - - - 0.00000M
Noncontrolling interest in consolidated entity - - - - 0.00000M
Temporary equity redeemable noncontrolling interests - - - - 0.00000M
Accumulated other comprehensive income - - - -0.02014M 0.00000M
Additional paid in capital - - - - 0.00000M
Common stock total equity - - 0.00142M 0.00055M 0.00387M
Preferred stock total equity - - - - 0.00000M
Retained earnings total equity - - -25.39580M - 0.00000M
Treasury stock - - - - 0.00000M
Accumulated amortization - - - - 0.00000M
Non currrent assets other 0.00553M 0.00553M 0.00553M 0.00553M 0.00553M
Deferred long term asset charges - - - - 0.00000M
Non current assets total 0.23M 8.14M 9.01M 9.88M 10.46M
Capital lease obligations 0.23M 0.08M 0.17M 0.23M 0.00000M
Long term debt total - - 0.04M - 0.00000M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - 0.00000M -0.02228M
Change to liabilities - -0.10179M 0.25M -0.21649M 0.24M
Total cashflows from investing activities - - - - -0.02228M
Net borrowings - - 0.86M 0.81M 0.81M
Total cash from financing activities -0.38884M 9.80M 17.87M 1.70M 2.62M
Change to operating activities - -1.08370M -0.38548M 0.04M -0.05271M
Net income -27.42423M -11.42753M -14.41379M -3.35788M -3.76505M
Change in cash -9.99399M 1.08M 14.72M -1.04943M -1.10647M
Begin period cash flow 16.50M 15.42M 0.69M 1.74M 2.85M
End period cash flow 6.50M 16.50M 15.42M 0.69M 1.74M
Total cash from operating activities -9.60514M -8.71729M -3.14320M -2.75014M -3.70791M
Issuance of capital stock 0.00000M 10.05M 17.10M 0.00000M 2.87M
Depreciation 0.79M 0.79M 0.80M 0.80M 0.63M
Other cashflows from investing activities - - - - 0.00000M
Dividends paid - - - - 0.00000M
Change to inventory - - - - 0.00000M
Change to account receivables - 0.00675M -0.07702M -0.07702M -0.07702M
Sale purchase of stock -0.38884M -0.06440M 17.10M - 0.00000M
Other cashflows from financing activities -0.08884M -0.18649M 0.77M 1.70M -0.25096M
Change to netincome - 3.10M 10.41M -0.01811M -0.82874M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M 0.02M
Change receivables - - -0.16221M - 0.00000M
Cash flows other operating - - 8.36M - 0.00000M
Exchange rate changes - - - - 0.00000M
Cash and cash equivalents changes - - 14.72M - 0.00000M
Change in working capital 0.54M -1.17874M -0.14039M -0.17971M 0.19M
Stock based compensation 8.83M 3.41M 2.73M 0.51M 0.07M
Other non cash items 7.66M 0.22M 8.88M 0.08M 0.07M
Free cash flow -9.60514M -8.71729M -3.14320M -2.75014M -3.72841M

Fundamentals

  • Previous Close 2.26
  • Market Cap11.07M
  • Volume88586
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-14.59011M
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-1.14

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
PCSA
Processa Pharmaceuticals Inc		 -0.09 3.98% 2.17 - - - 1.44 -0.2506
NVO
Novo Nordisk A/S		 -0.97 0.78% 123.05 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -2.71 2.18% 121.51 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.92 0.23% 401.08 30.40 24.75 10.68 6.25 9.52 20.36
CSLLY
CSL Ltd		 0.14 0.15% 91.19 42.45 26.95 7.05 5.80 7.85 26.51

Reports Covered

Stock Research & News

View All

Profile

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

Processa Pharmaceuticals Inc

7380 Coca Cola Drive, Hanover, MD, United States, 21076

Key Executives

Name Title Year Born
Dr. David Young Ph.D., Pharm.D. Co-Founder, Pres, CEO & Director 1953
Mr. Patrick Lin Co-Founder, Chief Bus. & Strategy Officer 1965
Dr. Sian E. Bigora Ph.D., Pharm.D. Co-Founder & Chief Devel. Officer 1960
Ms. Wendy J. Guy Co-Founder, Chief Admin. Officer & Corp. Sec. 1964
Mr. James H. Stanker Chief Financial Officer 1958
Mr. Robert Michael Floyd Chief Operating Officer 1956

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).